Stem Cells International

Stem Cells International / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 1916542 | 12 pages | https://doi.org/10.1155/2019/1916542

Angiogenic Properties of Menstrual Stem Cells Are Impaired in Women with a History of Preeclampsia

Academic Editor: Heinrich Sauer
Received20 Jul 2018
Revised05 Nov 2018
Accepted06 Dec 2018
Published27 Jan 2019

Abstract

Preeclampsia is a pregnancy-specific disorder defined by the new onset of hypertension and proteinuria after 20 weeks of gestation. Although its precise etiology is still unknown, there is evidence suggesting that it may be a consequence of impaired decidual and stromal cell function. Recently, a stem cell population derived from endometrial tissue and isolated from menstrual effluent called menstrual stem cells (MenSCs) has been identified. MenSCs exhibit important angiogenic and inflammatory properties that may contribute to both normal and pathological complications of implantation and placentation, including preeclampsia. We hypothesized that the angiogenic and inflammatory activity of MenSCs is altered in women who have a past history of preeclampsia and that this phenotype persists postpartum. The primary outcome measures were stromal progenitor cell formation, in vitro induction of endothelial tube formation, and release of proinflammatory cytokines. MenSCs obtained from women with a previous normal or preeclamptic pregnancy displayed similar phenotypic characteristics, tri-differentiation capacity, and proliferation. MenSCs derived from women who had preeclampsia on their previous pregnancy had reduced angiogenic capacity (~30% fewer junctions and nodes, ) and stromal progenitor cell formation (<50% measured at a serial dilution of 1 : 10.000, ) when compared to controls. In vitro, MenSCs obtained from patients with a history of preeclampsia expressed less endoglin and secreted less VEGF but more IL-6 than controls did. These data are consistent with the hypothesis that the angiogenic and inflammatory properties of MenSCs of women with a previous pregnancy complicated by preeclampsia have reduced angiogenic capacity and are more proinflammatory than those of MenSCs of women with a previous normal pregnancy. This altered phenotype of MenSCs observed following preeclampsia could either be present before the development of the pathology, predisposing the endometrial milieu to and consequently leading to limited vascular remodeling, or be a consequence of preeclampsia itself. The former may afford opportunity for targeted therapeutic intervention; the latter, a putative biomarker for future risk of pregnancy complications.

1. Introduction

Preeclampsia (PE) is a life-threatening vascular disorder of pregnancy due to a failing placenta that affects 3% to 5% of all pregnancies and is a major cause of maternal and perinatal morbidity and mortality [1]. PE is characterized by inadequate remodeling of uterine spiral arteries and reduced uteroplacental blood flow. These defects may be a consequence of shallow invasion by extravillous trophoblast cells [26], recruitment and function of maternal immune cells [711], endovascular trophoblast infiltration [2, 4, 12, 13], maturation of endometrial cells [14, 15], and decidual and stromal cell function [1518], but most likely it could be due to a combination of all of these factors [19, 20].

Recently, endometrial cells have demonstrated to play a central role in both normal and abnormal early pregnancy development [2131]. Notably, a growing body of evidence shows that defective endometrial cells and aberrant decidual response are implicated in the development of obstetrical syndromes such as PE [15, 3234]. In fact, decidualization disorders have been detected at the time of delivery and have been proposed to persist years after the affected pregnancy [14, 15, 18]. Thus, not only does this support the idea that endometrial cells could reflect abnormal processes occurring in PE, during the pregnancy, but it also suggests that even years after pregnancy the abnormal phenotype could remain.

In the past decade, a population of mesenchymal stem cells (MSCs) with endometrial origin has been identified and characterized from human endometrial tissue and menstrual fluid [35, 36]. The properties of MSCs isolated from menstrual fluid, called also menstrual stem cells (MenSCs), have been extensively characterized [3740]. Alcayaga-Miranda and colleagues showed that MenSCs display improved angiogenic properties, including VEGF secretion, in comparison with MSCs isolated from the bone marrow [40]. These data support the idea that MenSCs could reflect the status of the endometrium at the time of implantation and angiogenic changes occurring in normal and abnormal trophoblast invasion.

Although implantation and angiogenesis are both impaired in PE, the relation between the angiogenic properties of MSCs derived from the endometrium and the pathology of PE has not been evaluated. In this study, we characterized the phenotype of MenSCs isolated from women who previously developed PE (MenSCs-PE) in comparison with MenSCs isolated from healthy donors (MenSCs-C) in relation to their morphological, immunophenotypic, and functional characteristics. In a second phase, we evaluated the angiogenic properties of these cells by measuring their capacity of tube formation and secretion of the soluble factors, VEGF and endoglin, and cytokines that can modulate angiogenesis such as IL-6, IL-1β, and GM-CSF, among others.

2. Material and Methods

2.1. Study Design and Subjects

All human samples and cells used in this study were collected and harvested with the informed consent of the donor as approved by the ethical scientific committee of Clinica Davila and Universidad de los Andes. MenSCs were obtained from nine healthy donors (control) and six women who had PE on their previous pregnancies (9-12 months postpartum). Demographic characteristics were recorded. All women were using natural family planning, were not breastfeeding, had regular menses, and had not used contraceptives for at least 3 months before enrolment in the study.

2.2. Isolation and Culture of MenSCs

MenSCs were isolated as described previously [40]. Briefly, menstrual effluent was collected in a menstrual silicone cup (Mialuna, Santiago, Chile) during the first 48 h of the menstruation cycle and transferred into a 50 ml tube with 10 ml phosphate-buffered saline 1x (PBS) containing 0.25 mg/ml amphotericin B, 100 IU penicillin, 100 mg/ml streptomycin, and 2 mM ethylenediaminetetraacetic acid (EDTA) (Gibco, Thermo Fisher Scientific, MA, USA). MenSCs were separated from menstrual blood-mononuclear cells and other debris by Ficoll-Paque Plus density gradient (GE Healthcare, MI, USA) according to the manufacturer’s instructions and washed in PBS. Subsequently, cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 1% penicillin/streptomycin (P/S), 1% amphotericin B, 1% glutamine (Gibco), and 15% fetal bovine serum (FBS) (HyClone, GE Healthcare) at 37°C, 5% CO2. Media were changed the day after to remove any nonadherent cells. All experiments were performed using MenSCs at early passages (P) P2 to P6. All cells tested negative for mycoplasma.

2.3. Phenotypic Characterization of MenSCs

For phenotypic characterization, cells were harvested, washed with cytometer buffer (PBS + 0.2% BSA + 0.01% sodium azide (Sigma-Aldrich, MI, USA)), and incubated with the specific labelled antibodies in cytometer buffer for 20 min at 4°C. Antibodies for human cell surface antigens CD14, CD44, CD90, CD105, CD73, CD45, CD34, HLA-ABC, HLA-DR, and CD146 were purchased from BD Biosciences, MD, USA, R&D Systems, MN, USA, and BioLegend, CA, USA. Matching isotype antibodies were used as negative controls in all experiments. In addition, LIVE/DEAD® Fixable dead cell stain kit (Invitrogen, CA, USA) was used to determine the viability of cells by flow cytometry according to the manufacturer’s protocol. Data were collected using a fluorescence-activated cell sorting (FACS) Canto II flow cytometer (BD Biosciences) and analyzed on the FlowJo analysis software.

2.4. Tri-Differentiation Assay

MenSCs were induced to differentiation into chondrogenic, osteogenic, and adipogenic lineages using specific media over 21 days. For osteogenic differentiation, media were composed of DMEM high glucose (Corning, MA, USA) supplemented with FBS 5% (Gibco), 155 nM ascorbic acid (Sigma), 10 μM β-glycerophosphate (Sigma-Aldrich), 0.1 μM dexamethasone (Sigma-Aldrich), 2 mM L-glutamine (Gibco), and 100 U/ml penicillin-streptomycin. Differentiation was evaluated for genetic evaluation. Briefly, cells were lysed with TRIzol™ Reagent (Thermo Fisher), and RNA extraction was performed according to the manufacturer’s instructions. 2 μg of RNA was used for reverse transcription using the SuperScript II enzyme (Thermo Fisher), and cDNA was stored at –20°C until further analysis. qPCR was carried out using Brilliant II SYBR Green qPCR Master Mix (Stratagene, CA, USA) according to the manufacturer’s instructions and amplified with qPCR System 3000X (Stratagene). GAPDH was used as a housekeeping gene for normalization. Primers’ details are provided in Table 1.


GeneLineagePrimer

RunX2 FOsteogenicCGG AAT GCC TCT GCT GTT AT
RunX2 ROsteogenicTTC CCG AGG TCC ATC TAC TG
Osteocalcin FOsteogenicGGC GCT ACC TGT ATC AAT GG
Osteocalcin ROsteogenicTCA GCC AAC TCG TCA CAG TC
FABP4 FAdipogenicATG GGA TGG AAA ATC AAC CA
FABP4 RAdipogenicGTG GAA GTG ACG CCT TTC AT
PPAR-γ FAdipogenicATG GAG TCC ACG AGA TCA TT
PPAR-γ RAdipogenicCGC AGG CTC TTT AGA AAC TC
GAPDH FHousekeepingCAG CCT CAA GAT CAT CAG CA
GAPDH RHousekeepingCAT GAG TCC TTC CAC GAT AC

2.5. Colony-Forming Unit Assay

To quantify the frequency of stromal progenitors, cells obtained after Ficoll centrifugation of the menstrual effluent were plated at a density of 100, 1,000, 10,000, and 100,000 nucleated cells/cm2 in DMEM. The medium was changed the next day to remove nonadherent cells. The frequency of progenitors was calculated following the extreme limiting dilution analysis (ELDA) method for comparing depleted and enriched populations in stem cells [40]. To quantify functional MSCs, MenSCs from both groups were evaluated for frequency of colony-forming units (CFU). CFU in passage 4 (P4) were evaluated in a serial dilution assay, where 25 to 250 cells per well were seeded in a 6-well plate (Falcon, Corning). After 14 days, colonies were stained with 0.5% crystal violet (Sigma-Aldrich) in 10% methanol for 20 min. Colonies formed by more than 50 cells were counted under a light microscope at low magnification. Results were expressed as CFU/number of cells plated.

2.6. Proliferation Assay

MenSCs were cultured at 1,000 cells/cm2 in 24-well plates (Falcon, Corning) in complete DMEM (10% FBS, 1% penicillin-streptomycin). Cell proliferation and viability were determined at days 3, 6, and 9 by the SRB Assay (BioVision, CA, USA) and by spectrophotometric quantification (absorbance, 492 nm) according to the manufacturer’s instructions.

2.7. Decidualization Recapitulated In Vitro

MenSCs were cultured under an endometrial hormonal milieu. Briefly, 120,000 MenSCs were cultured in a 6-well plate with complete DMEM without phenol red (Gibco) and exposed to 5% oxygen conditions (5% O2). 24 h after, the medium was replaced with DMEM without phenol red and 10% FBS, treated with active carbon and 1% penicillin-streptomycin, supplemented with estrogen (E2; 213 pg/ml, Sigma-Aldrich, MI, USA), and cultured at 5% O2 for 24 h. The medium was replaced for the same media described above but supplemented with both estrogen and progesterone (E2; 146 pg/ml, P4; 11 ng/ml, respectively, Sigma-Aldrich, MI, USA) and cultured at 5% O2. 24 h later, conditioned media were harvested, centrifuged at 500 g for 5 min, and stored at -80°C for subsequent analysis: angiogenesis assay, ELISA, and protein solution array assays (Luminex Corporation, TX, USA). MenSC cellular lysates were collected for Western blot analysis.

2.8. Angiogenesis Assay

Tube formation in Matrigel (Corning) was used as a functional assay to evaluate the angiogenic properties of MenSCs. Briefly, human umbilical vein endothelial cells (HUVECs) were seeded in 48-well plates precoated with 70 μl of growth factor reduced Matrigel (Corning, Manassas, VA, USA) at a density of cells/well in the conditioned medium harvested previously. After 16 hours, the tube formation was examined by phase-contrast and the images were captured using an Olympus U-RFL-T camera. Junctions, nodes, meshes, and branches of tubes were analyzed using the ImageJ Angiogenesis Analyzer software.

2.9. Western Blot

Protein lysates were extracted from MenSCs exposed to endometrial conditions using RIPA buffer. Protein concentration was measured using the Qubit Protein Assay kit (Thermo Fisher Scientific), and 5 μg of proteins was separated on a 12% polyacrylamide gel and transferred to polyvinylidene difluoride membrane (PVDF, Thermo Scientific). The membrane was blocked with 5% skimmed milk in PBS 1x Tween 0.1% (PBS 10x, Corning; Tween 20, Winkler) for 1 h at room temperature and then incubated overnight at 4°C with anti-VEGF (cat# ab183100, 1 : 1.000, Abcam, Cambridge, United Kingdom), anti-endoglin (cat# ab137389, 1 : 1.000, Abcam, Cambridge, United Kingdom), or β-actin (cat# Ab183100, 1 : 1,000, Abcam, Cambridge, United Kingdom). After overnight incubation, membranes were washed and exposed for 2 h to the anti-rabbit secondary antibody (cat# 474-1506, 1 : 10,000, Kirkegaard & Perry Lab Inc., Gaithersburg, MD) to VEGF and endoglin and anti-mouse secondary antibody (cat# ab6276, 1 : 10,000, Kirkegaard & Perry Lab Inc., Gaithersburg, MD) to β-actin. The signal was detected with horseradish peroxidase-linked anti-rabbit or anti-mouse (KPL), and chemiluminescence was visualized using the ECL detection system (Thermo Fisher Scientific, Waltham, MA).

2.10. Quantification of Angiogenic Secreted Factors by ELISA

The conditioned medium harvested from MenSCs cultured under an endometrial hormonal microenvironment was concentrated using 10 kDa Amicon Ultra-4 filters (Millipore, St. Charles, MO, USA), and the protein concentration of the concentrated conditioned medium was measured using the Qubit Protein Assay kit (Thermo Fisher Scientific). VEGF, soluble endoglin (sEng), soluble fms-like tyrosine kinase-1 (sFlt1), angiopoietin 1, and angiopoietin 2 concentrations were detected using ELISA kits (VEGF, cat# DY293B; endoglin, cat# DY1097; sFlt1, cat# DVR100C; angiopoietin 1, cat# DANG10; and angiopoietin-2, cat# DANG20; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol.

2.11. Proinflammatory Cytokine Profile

The secreted cytokine profile was determined using a commercial 11-multiplex fluorescent bead-based immunoassay (R&D Systems). The concentration of the following cytokines was determined: IL-8, IFN-γ, IL-1β, IL-12p70, IL-2, TNF-α, GM-CSF, IL-1α, IL-10, IL-17A, and IL-6. The same concentrated conditioned medium from the ELISA analysis was used. Briefly, 50 μl of the concentrated conditioned medium was incubated with diluted bead cocktail for 2 h, with constant shaking at room temperature. The beads were washed and incubated with detection antibodies for 1 h with constant shaking at room temperature. The beads were washed, and streptavidin-PE was added and allowed to incubate for 30 min with constant shaking at room temperature (in the dark). The beads were then washed and suspended in 100 μl of wash buffer and incubated for 2 min on the shaker prior to reading. Fluorescence was determined on the MAGPIX® System (Thermo Fisher Scientific), and the cytokine concentrations for each sample were extrapolated based on standards utilizing Milliplex Analyst 5.1 software (Millipore) with a 4-parameter logistic curve (4-PL).

2.12. Statistical Analyses

Statistical analyses were performed using the -test, and statistical significance was set at . Data was analyzed using the GraphPad Prism 6.0 program (GraphPad Software, La Jolla, CA, USA).

3. Results

The demographic characteristics of the PE (case group) and control groups are presented in Table 2. No significant differences were observed in age, weight, and height in both groups. BMI was higher in the women with a history of PE in comparison with healthy controls (). In terms of obstetric history, the healthy women (control group) were a mixture between nulliparous (4) and multiparous (5).


CharacteristicsControl ()PE () value

Age (years), median (IQ)29.00 (28.00-33.00)30.50 (26.75-34.25)0.9319
Weight (kg), median (IQ)60.00 (53.50-68.00)73.50 (59.00-83.75)0.0939
Height (mt), median (IQ)1.650 (1.610-1.690)1.605 (1.573-1.658)0.2302
BMI (kg/cm2), median (IQ)22.00 (19.40-24.80)27.30 (23.18-33.68)0.0496
Nullipara, (%)4 (44.4)0 (0)
Miscarriages, (%)1 (11.1)1 (16.7)
Early PE, (%)4 (66.7)
Late PE, (%)2 (33.3)
Early PE (weeks), median (IQ)27.5 (24.5-27.5)
Late PE, (weeks) median (IQ)37.1 (36.4-37.7)

Abbreviations: kg: kilograms; mt: meters; BMI: body mass index (kilograms/square meters). Results are (interquartile). Statistical analysis was performed using Student’s -tests. , significant.

For case and control groups, MenSC morphology, phenotypic characteristics, and potential to differentiate into adipocytes, osteoblasts, and chondrocytes were compared. Both cases and controls displayed similar fibroblast-like morphology (Figure 1(a)); expression of the classical MSC positive markers CD90, CD73, CD105, and CD44; absence of the negative markers CD14, CD34, CD45, and HLA-DR (Figure 1(b)); and capacity to differentiate into osteogenic, adipogenic, (Figures 1(c) and 1(d)), and chondrogenic lineages (Supplementary Figure 1). No difference was observed in the expression of pluripotency genes OCT4, SOX2, and NANOG (Supplementary Figure 2).

To compare functional properties of MenSCs, the proliferative and clonogenic potential of these cells was assessed. The proliferation rate was similar in both case and control groups (Figure 2(a)). The initial clonogenic capacity of MenSCs isolated from women with a previous pregnancy complicated by preeclampsia, however, was reduced when compared to controls (Figure 2(b)), with reduced initial frequency of mesenchymal progenitors (PE: 1 in 874 with 95% confidence interval (CI) of 1/471 to 1/1620; control: 1 in 358 with 95% confidence interval (CI) of 1/227 to 1/566) (Supplementary Figure 3). The frequency of CFU after cell expansion in high dilutions was also reduced in MenSCs isolated from women with a history of preeclampsia (Figures 2(c) and 2(d)). We have also evaluated the gene expression of metalloproteinase-3 (MMP-3), a gene involved in MSC migration, and we observed a significant decrease in the MMP-3 mRNA expression in the MenSCs derived from women with a past history of PE (Supplementary Figure 4).

Since the human uterus is exposed to oxygen tensions of 2-5% [41] and varying hormonal profiles throughout the menstrual cycle [42], MenSC angiogenic activity was assessed under conditions that recapitulated the decidualization microenvironment of the human menstrual cycle in vitro. The implantation window during a normal menstrual cycle is characterized by increased VEGF and leukemia inhibitory factor (LIF) expression. This expression profile was recapitulated in MenSCs from healthy donors incubated in vitro under an environment that mimics the receptive phase (Supplementary Figure 5).

MenSCs isolated from women with a previous pregnancy complicated by PE have reduced angiogenic capacity compared to controls (Figure 3(a)). The quantification of different parameters of tube formation showed a significant decrease of approximately 30% in junctions and nodes (Figure 3(b)). No significant differences were identified in meshes or branches (Figure 3(b)).

VEGF protein expression (Figures 4(a) and 4(b)) and secretion to the culture media (Figure 4(c) and Table 3) were reduced in cases compared to controls. MenSCs from the PE group expressed less endoglin (Figures 4(d) and 4(e)); however, no statistically significant change was identified in secretion (Figure 4(f) and Table 3). Similarly, no statistically significant changes were identified in sFlt1, angiopoietin-1, or angiopoietin-2 concentrations (Table 3). IL-6 secretion from MenSCs from the PE group was 2.3-fold greater than that observed for controls (Figure 5 and Table 4). No significant differences were observed in the secretion levels of IL-1β, GM-CSF, TNF-α, IL-8, IL-10, IFN-γ, IL-1α, IL-17A, IL-2, and IL-12p70 (Figure 5 and Table 4).


CharacteristicsControl ()PE () value

VEGF (pg/ml)/mg total protein, median (IQ)20.05 (13.70-45.18)11.40 (5.438-17.60)0.0233
sEng (ng/ml)/mg total protein, median (IQ)0.066 (0.042-0.082)0.088 (0.061-0.1845)0.0637
sFlt1 (pg/ml)/mg total protein, median (IQ)81.38 (30.43-117.2)91.36 (20.39-281.3)0.3826
Angiopoietin-1 (pg/ml)/mg total protein, median (IQ)103.3 (28.99-168.9)136.3 (48.26-239.7)0.2264
Angiopoietin-2 (pg/ml)/mg total protein, median (IQ)59.75 (40.76-128.9)61.34 (37.49-127.7)0.3275

Abbreviations: VEGF: vascular endothelial growth factor; sEng: soluble endoglin; sFlt1: soluble fms-like tyrosine kinase-1; pg: picograms; ng: nanograms; ml: milliliters; mg: milligrams. Results are (interquartile). Statistical analysis was performed using Student’s -tests. , significant.

CharacteristicsControl ()PE () value

IL-8 (pg/ml)/mg total protein, median (IQ)1359 (424.2-1423)1355 (1126-1380)0.4645
IFN-γ (pg/ml)/mg total protein, median (IQ)4.913 (2.613-6.524)5.465 (3.825-7.933)0.2757
IL-1β (pg/ml)/mg total protein, median (IQ)2.857 (0.697-3.694)4.418 (3.862-5.020)0.0571
IL-12p70 (pg/ml)/mg total protein, median (IQ)7.911 (3.598-10.04)9.369 (5.741-12.16)0.2537
IL-2 (pg/ml)/mg total protein, median (IQ)6.623 (5.346-7.394)6.882 (4.991-9.218)0.3247
TNF-α (pg/ml)/mg total protein, median (IQ)1.178 (0.389-1.699)1.296 (0.855-2.405)0.2428
GM-CSF (pg/ml)/mg total protein, median (IQ)17.55 (9.24-37.64)34.20 (22.45-130.3)0.0745
IL-1α (pg/ml)/mg total protein, median (IQ)2.402 (1.183-3.586)2.619 (1.581-5.668)0.3423
IL-10 (pg/ml)/mg total protein, median (IQ)0.336 (0.209-0.366)0.274 (0.220-0.375)0.4382
IL-17A (pg/ml)/mg total protein, median (IQ)1.095 (0.619-1.363)1.370 (0.753-1.630)0.2194
IL-6 (pg/ml)/mg total protein, median (IQ)228.6 (23.40-450.8)349.8 (299.8-1032)0.0145

Abbreviations: pg: picograms; ml: milliliters; mg: milligrams. Results are (interquartile). Statistical analysis was performed using Student’s -tests. , significant.

Since decidualization has been related to the development of PE, we evaluated the mRNA expression of genes involved in the decidualization process, such as IGFBP-1 and TGF-β [43, 44], but we did not observe a reduction in the mRNA expression of both genes on MenSCs from women with a history of PE (Supplementary Figure 6).

4. Discussion

The menstrual fluid is generally considered to represent a combination of blood and desquamated cells from the endometrium, many of which are nonviable or in a senescent state. A subpopulation of these cells displays stem cell properties, including angiogenic activity. The data obtained in this study suggest that these cells retain phenotypic variations postpartum that may be associated with and account for the abnormal implantation process observed in preeclampsia. MenSCs obtained from women with a previous preeclamptic pregnancy express less VEGF and membrane-bound endoglin, induce less endothelial cell tube formation, and release more IL-6 than do cells obtained from women with a normotensive previous pregnancy or from women that were never pregnant. The observed phenotypic variations are constituent with the pathophysiology of PE.

Different studies have shown the importance of endometrial cells in the natural selection of human embryos in the process of implantation [27, 45] and as revealed by a recent study that endometrial stromal cell secretome is associated with embryo implantation failure [46]. VEGF is one of the secreted factors contributing to successful implantation [47, 48] due to its control of the angiogenic process that is tightly regulated during the menstrual cycle [4951]. Moreover, mice treated with the angiogenic inhibitor AGM-1470 present impaired endometrial maturation and decidualization affecting the embryo development and implantation [52]. Likewise, administration of VEGF antibodies affected the endometrial vascular permeability in rats, another event associated with implantation [53]. According to our results, VEGF expression on MenSC-PE is decreased, even one year after pregnancy, highlighting the potential role of these cells in the abnormal angiogenic process of implantation of patients with a history of PE.

Decidualization induces a switch in the secretion of different secreted factors around the perivascular niche to promote trophoblast invasion and to regulate immune response. Decidualization defects have been described to be involved in the development of PE [14, 15, 18]. In fact, it has been proposed that analysis of the decidual response could determine the risk of placental disorders in women [54]. Moreover, in PE, decidualization disorders have been detected at the time of delivery and may persist years after the affected pregnancy. Human endometrial stromal cells (hESC) obtained from nonpregnant women with a history of severe PE do not decidualize in vitro in response to cAMP and medroxyprogesterone acetate and release significantly less decidualization markers (prolactin and IGFBP-1) than do those derived from women with a previous normal pregnancy. Similarly, decidual cells (from the decidua basalis and parietalis) obtained from pregnant women with severe PE do not express decidualization markers (IGFBP-1 and prolactin) in comparison with a gestational age-matched control group and do not redecidualize in vitro [18]. Importantly, circulating concentrations of IGFBP-1 are lower in pregnant patients who subsequently develop PE than in those with a normal pregnancy outcome [55, 56]. Furthermore, decidual cell-conditioned media from patients with severe PE do not promote cytotrophoblast invasion; however, this defect is corrected by the addition of prolactin and IGFBP-1 [18]. Our results showed a decrease in the IGFBP-1 on MenSC-PE, establishing that these anomalies are related not only to impaired decidualization but also to an impaired angiogenesis, highlighting the potential importance of the cells present in the decidua in the pathogenesis of preeclampsia.

Venkatesha and collaborators showed that soluble endoglin (sEng) plays an important role in the pathogenesis of PE affecting the placental vascular function [57]. During normal pregnancy, sEng liberation is inhibited from the placenta and endothelium through proinflammatory cytokines such as TNF-α and IFN-γ, but in a preeclamptic pregnancy sEng is increased along with sFlt-1 before the onset of the clinical symptoms of preeclampsia [58, 59]. Although previous studies have investigated the mechanism of sEng secretion and function of membrane-bound endoglin on endothelial cells and angiogenesis [57], there is contradictory information about the tissue origin of circulating sEng during preeclampsia. A recent in vitro study confirms that pAkt/Akt is reduced in preeclamptic placentas and suggests that sEng originates from endothelial cells and not from the placenta cells [60]. Although this study provided valuable data, it was unable to demonstrate that this reduction contributes to excessive sEng release from placenta. Recently, Chadchan et al. explored the role of endoglin in the uterine receptivity for embryo implantation in a murine model and identified increased endoglin expression in the endometrium during the implantation window and a reduced implantation index following endoglin knockdown [61]. Our results highlight the potential importance of the membrane-bound endoglin during the implantation window and the impairment of its expression in patients with history of PE. In addition, our data are consistent with an endometrial stem cell contribution to increased plasma sEng concentrations during preeclampsia.

In addition to changes in Eng on MenSC-PE, we also observed an increased secretion of IL-6 from these cells. Indeed, PE has been associated with an immune imbalance which induces a systemic inflammation [62]. In patients with PE, the decidua basalis shows abnormal T-regulatory cell function, as well as changes in macrophage number and phenotype, and an increase in proinflammatory cytokine expression, including IL-6 [6365]. Interestingly, IL-6 has been implicated to stimulate a defective angiogenesis in tumor models [66]. Moreover, IL-6 has also been described as a cytokine with endometrial function and with a role in implantation [67]. Our results are consistent with the idea that mesenchymal stem cells present in the decidua could be contributing to the development of PE by releasing factors such as IL-6. Future studies will be needed in order to clarify how MenSCs could contribute to the preeclampsia pathogenesis, but preliminarily, our results suggest a role for these cells in mediating both angiogenesis impairment and potentially inflammation.

5. Conclusions

In summary, previous studies suggest that endometrial stromal cells obtained from individual patients closely phenocopy the decidualization process. Menstrual fluid contains a subpopulation of mesenchymal stem cells of endometrial origin. Menstrual stem cells from women who had a previous preeclampsia display different angiogenic and inflammatory properties than do those obtained from patients who had a previous normal pregnancy. These data may be useful in the development of predictive models to identify patients at risk of preeclampsia in the preconceptional stage.

Data Availability

The data used to support the findings of this study are included within the article and within the supplementary information file(s).

Conflicts of Interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Authors’ Contributions

Manuel Varas-Godoy and Stephanie Acuña-Gallardo contributed equally to this work.

Acknowledgments

This work was funded by Comisión Nacional de Investigación Científica y Tecnológica: Fondecyt 1140119 to Sebastian E. Illanes and Fondecyt 11150624 to Manuel Varas-Godoy. We thank the technical expertise and support of Alex Cabrera in the flow cytometry experiments and Pía Venegas for her valuable contribution to the sample collection and patient recruitment.

Supplementary Materials

Supplementary Figures_Final: file with the legends of each Supplementary Figures. Supplementary Material_Final: file with all the methods related to the experiments performed for the Supplementary Figures. Supplementary Figure 1, 2, 3, 4, 5 and 6: supplementary figures in EPS format. The description of each figure is in the Supplementary Figures_Final file. (Supplementary Materials)

References

  1. B. W. J. Mol, C. T. Roberts, S. Thangaratinam, L. A. Magee, C. J. M. de Groot, and G. J. Hofmeyr, “Pre-eclampsia,” The Lancet, vol. 387, no. 10022, pp. 999–1011, 2016. View at: Publisher Site | Google Scholar
  2. F. Lyall, J. N. Bulmer, E. Duffie, F. Cousins, A. Theriault, and S. C. Robson, “Human trophoblast invasion and spiral artery transformation: the role of PECAM-1 in normal pregnancy, preeclampsia, and fetal growth restriction,” The American Journal of Pathology, vol. 158, no. 5, pp. 1713–1721, 2001. View at: Publisher Site | Google Scholar
  3. T. Naicker, S. M. Khedun, J. Moodley, and R. Pijnenborg, “Quantitative analysis of trophoblast invasion in preeclampsia,” Acta Obstetricia et Gynecologica Scandinavica, vol. 82, no. 8, pp. 722–729, 2003. View at: Publisher Site | Google Scholar
  4. P. Kaufmann, S. Black, and B. Huppertz, “Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia,” Biology of Reproduction, vol. 69, no. 1, pp. 1–7, 2003. View at: Publisher Site | Google Scholar
  5. R. Pijnenborg, J. Anthony, D. Davey et al., “Placental bed spiral arteries in the hypertensive disorders of pregnancy,” British Journal of Obstetrics and Gynaecology, vol. 98, no. 7, pp. 648–655, 1991. View at: Publisher Site | Google Scholar
  6. J. M. Roberts and H. S. Gammill, “Preeclampsia: recent insights,” Hypertension, vol. 46, no. 6, pp. 1243–1249, 2005. View at: Publisher Site | Google Scholar
  7. A. Alanen and O. Lassila, “Deficient natural killer cell function in preeclampsia,” Obstetrics and Gynecology, vol. 60, no. 5, pp. 631–634, 1982. View at: Google Scholar
  8. R. Fraser, G. S. J. Whitley, A. P. Johnstone et al., “Impaired decidual natural killer cell regulation of vascular remodelling in early human pregnancies with high uterine artery resistance,” The Journal of Pathology, vol. 228, no. 3, pp. 322–332, 2012. View at: Publisher Site | Google Scholar
  9. A. E. Wallace, R. Fraser, S. Gurung et al., “Increased angiogenic factor secretion by decidual natural killer cells from pregnancies with high uterine artery resistance alters trophoblast function,” Human Reproduction, vol. 29, no. 4, pp. 652–660, 2014. View at: Publisher Site | Google Scholar
  10. S. E. Hiby, J. J. Walker, K. M. O'Shaughnessy et al., “Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success,” The Journal of Experimental Medicine, vol. 200, no. 8, pp. 957–965, 2004. View at: Publisher Site | Google Scholar
  11. S. Xiong, A. M. Sharkey, P. R. Kennedy et al., “Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation,” The Journal of Clinical Investigation, vol. 123, no. 10, pp. 4264–4272, 2013. View at: Publisher Site | Google Scholar
  12. Y. Zhou, C. H. Damsky, and S. J. Fisher, “Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?” The Journal of Clinical Investigation, vol. 99, no. 9, pp. 2152–2164, 1997. View at: Publisher Site | Google Scholar
  13. F. Lyall, S. C. Robson, and J. N. Bulmer, “Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome,” Hypertension, vol. 62, no. 6, pp. 1046–1054, 2013. View at: Publisher Site | Google Scholar
  14. M. B. Rabaglino, E. D. Post Uiterweer, A. Jeyabalan, W. A. Hogge, and K. P. Conrad, “Bioinformatics approach reveals evidence for impaired endometrial maturation before and during early pregnancy in women who developed preeclampsia,” Hypertension, vol. 65, no. 2, pp. 421–429, 2015. View at: Publisher Site | Google Scholar
  15. K. P. Conrad, M. B. Rabaglino, and E. D. Post Uiterweer, “Emerging role for dysregulated decidualization in the genesis of preeclampsia,” Placenta, vol. 60, pp. 119–129, 2017. View at: Publisher Site | Google Scholar
  16. P. K. Lala and P. Nandi, “Mechanisms of trophoblast migration, endometrial angiogenesis in preeclampsia: the role of decorin,” Cell Adhesion & Migration, vol. 10, no. 1-2, pp. 111–125, 2016. View at: Publisher Site | Google Scholar
  17. A. C. Staff, B. Halvorsen, T. Ranheim, and T. Henriksen, “Elevated level of free 8-iso-prostaglandin F2α in the decidua basalis of women with preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 181, no. 5, pp. 1211–1215, 1999. View at: Publisher Site | Google Scholar
  18. T. Garrido-Gomez, F. Dominguez, A. Quiñonero et al., “Defective decidualization during and after severe preeclampsia reveals a possible maternal contribution to the etiology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 40, pp. E8468–E8477, 2017. View at: Publisher Site | Google Scholar
  19. R. H. Choudhury, C. E. Dunk, S. J. Lye, J. D. Aplin, L. K. Harris, and R. L. Jones, “Extravillous Trophoblast and endothelial cell crosstalk mediates leukocyte infiltration to the early remodeling decidual spiral arteriole wall,” Journal of Immunology, vol. 198, no. 10, pp. 4115–4128, 2017. View at: Publisher Site | Google Scholar
  20. A. E. Wallace, A. J. Host, G. S. Whitley, and J. E. Cartwright, “Decidual natural killer cell interactions with trophoblasts are impaired in pregnancies at increased risk of preeclampsia,” The American Journal of Pathology, vol. 183, no. 6, pp. 1853–1861, 2013. View at: Publisher Site | Google Scholar
  21. E. S. Lucas, N. P. Dyer, K. Fishwick, S. Ott, and J. J. Brosens, “Success after failure: the role of endometrial stem cells in recurrent miscarriage,” Reproduction, vol. 152, no. 5, pp. R159–R166, 2016. View at: Publisher Site | Google Scholar
  22. E. M. Ramsey, M. L. Houston, and J. W. S. Harris, “Interactions of the trophoblast and maternal tissues in three closely related primate species,” American Journal of Obstetrics & Gynecology, vol. 124, no. 6, pp. 647–652, 1976. View at: Publisher Site | Google Scholar
  23. S. Christensen, H. G. Verhage, G. Nowak et al., “Smooth muscle myosin II and alpha smooth muscle actin expression in the baboon (Papio anubis) uterus is associated with glandular secretory activity and stromal cell transformation,” Biology of Reproduction, vol. 53, no. 3, pp. 598–608, 1995. View at: Publisher Site | Google Scholar
  24. B. Gellersen, I. A. Brosens, and J. J. Brosens, “Decidualization of the human endometrium: mechanisms, functions, and clinical perspectives,” Seminars in Reproductive Medicine, vol. 25, no. 6, pp. 445–453, 2007. View at: Publisher Site | Google Scholar
  25. G. Krikun, C. J. Lockwood, V. M. Abrahams, G. Mor, M. Paidas, and S. Guller, “Expression of toll-like receptors in the human decidua,” Histology and Histopathology, vol. 22, no. 8, pp. 847–854, 2007. View at: Publisher Site | Google Scholar
  26. J. J. Brosens and B. Gellersen, “Something new about early pregnancy: decidual biosensoring and natural embryo selection,” Ultrasound in Obstetrics and Gynecology, vol. 36, no. 1, pp. 1–5, 2010. View at: Publisher Site | Google Scholar
  27. G. Teklenburg, M. Salker, M. Molokhia et al., “Natural selection of human embryos: decidualizing endometrial stromal cells serve as sensors of embryo quality upon implantation,” PLoS One, vol. 5, no. 4, article e10258, 2010. View at: Publisher Site | Google Scholar
  28. M. S. Salker, J. Nautiyal, J. H. Steel et al., “Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss,” PLoS One, vol. 7, no. 12, article e52252, 2012. View at: Publisher Site | Google Scholar
  29. S. Quenby and J. J. Brosens, “Human implantation: a tale of mutual maternal and fetal attraction,” Biology of Reproduction, vol. 88, no. 3, 2013. View at: Publisher Site | Google Scholar
  30. J. J. Brosens, M. S. Salker, G. Teklenburg et al., “Uterine selection of human embryos at implantation,” Scientific Reports, vol. 4, article 3894, 2014. View at: Google Scholar
  31. N. S. Macklon and J. J. Brosens, “The human endometrium as a sensor of embryo quality,” Biology of Reproduction, vol. 91, no. 4, 2014. View at: Publisher Site | Google Scholar
  32. B. Gellersen and J. J. Brosens, “Cyclic decidualization of the human endometrium in reproductive health and failure,” Endocrine Reviews, vol. 35, no. 6, pp. 851–905, 2014. View at: Publisher Site | Google Scholar
  33. E. R. Norwitz, E. A. Bonney, V. V. Snegovskikh et al., “Molecular regulation of parturition: the role of the decidual clock,” Cold Spring Harbor Perspectives in Medicine, vol. 5, no. 11, 2015. View at: Publisher Site | Google Scholar
  34. P. Sebastian-Leon, N. Garrido, J. Remohi, A. Pellicer, and P. Diaz-Gimeno, “Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure,” Human Reproduction, vol. 33, no. 4, pp. 626–635, 2018. View at: Publisher Site | Google Scholar
  35. C. E. Gargett, K. E. Schwab, R. M. Zillwood, H. P. T. Nguyen, and D. Wu, “Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium,” Biology of Reproduction, vol. 80, no. 6, pp. 1136–1145, 2009. View at: Publisher Site | Google Scholar
  36. X. Meng, T. E. Ichim, J. Zhong et al., “Endometrial regenerative cells: a novel stem cell population,” Journal of Translational Medicine, vol. 5, no. 1, p. 57, 2007. View at: Publisher Site | Google Scholar
  37. N. Hida, N. Nishiyama, S. Miyoshi et al., “Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells,” Stem Cells, vol. 26, no. 7, pp. 1695–1704, 2008. View at: Publisher Site | Google Scholar
  38. X. Du, Q. Yuan, Y. Qu, Y. Zhou, and J. Bei, “Endometrial mesenchymal stem cells isolated from menstrual blood by adherence,” Stem Cells International, vol. 2016, Article ID 3573846, 8 pages, 2016. View at: Publisher Site | Google Scholar
  39. A. N. Patel, E. Park, M. Kuzman, F. Benetti, F. J. Silva, and J. G. Allickson, “Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation,” Cell Transplantation, vol. 17, no. 3, pp. 303–311, 2008. View at: Publisher Site | Google Scholar
  40. F. Alcayaga-Miranda, J. Cuenca, P. Luz-Crawford et al., “Characterization of menstrual stem cells: angiogenic effect, migration and hematopoietic stem cell support in comparison with bone marrow mesenchymal stem cells,” Stem Cell Research & Therapy, vol. 6, no. 1, p. 32, 2015. View at: Publisher Site | Google Scholar
  41. Z. F. Peng, S. L. Shi, H. X. Jin et al., “Impact of oxygen concentrations on fertilization, cleavage, implantation, and pregnancy rates of in vitro generated human embryos,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 4, pp. 6179–6185, 2015. View at: Google Scholar
  42. S. F. Liu, Z. X. Wang, Y. E. Yuan et al., “Hormone changes during the menstrual cycle of Chinese women,” Journal of Reproduction and Fertility, vol. 76, no. 1, pp. 43–52, 1986. View at: Google Scholar
  43. H. Matsumoto, K. Sakai, and M. Iwashita, “Insulin-like growth factor binding protein-1 induces decidualization of human endometrial stromal cells via α5β1 integrin,” Molecular Human Reproduction, vol. 14, no. 8, pp. 485–489, 2008. View at: Publisher Site | Google Scholar
  44. N. M. Kane, M. Jones, J. J. Brosens, R. W. Kelly, P. T. K. Saunders, and H. O. D. Critchley, “TGFβ1 attenuates expression of prolactin and IGFBP-1 in decidualized endometrial stromal cells by both SMAD-dependent and SMAD-independent pathways,” PLoS One, vol. 5, no. 9, article e12970, 2010. View at: Publisher Site | Google Scholar
  45. M. Salker, G. Teklenburg, M. Molokhia et al., “Natural selection of human embryos: impaired decidualization of endometrium disables embryo-maternal interactions and causes recurrent pregnancy loss,” PLoS One, vol. 5, no. 4, article e10287, 2010. View at: Publisher Site | Google Scholar
  46. R. R. Peter Durairaj, A. Aberkane, L. Polanski et al., “Deregulation of the endometrial stromal cell secretome precedes embryo implantation failure,” Molecular Human Reproduction, vol. 23, no. 7, pp. 478–487, 2017. View at: Publisher Site | Google Scholar
  47. N. J. Hannan, P. Paiva, K. L. Meehan, L. J. F. Rombauts, D. K. Gardner, and L. A. Salamonsen, “Analysis of fertility-related soluble mediators in human uterine fluid identifies VEGF as a key regulator of embryo implantation,” Endocrinology, vol. 152, no. 12, pp. 4948–4956, 2011. View at: Publisher Site | Google Scholar
  48. N. K. Binder, J. Evans, D. K. Gardner, L. A. Salamonsen, and N. J. Hannan, “Endometrial signals improve embryo outcome: functional role of vascular endothelial growth factor isoforms on embryo development and implantation in mice,” Human Reproduction, vol. 29, no. 10, pp. 2278–2286, 2014. View at: Publisher Site | Google Scholar
  49. C. E. Gargett and P. A. Rogers, “Human endometrial angiogenesis,” Reproduction, vol. 121, no. 2, pp. 181–186, 2001. View at: Publisher Site | Google Scholar
  50. D. S. Torry, J. Leavenworth, M. Chang et al., “Angiogenesis in implantation,” Journal of Assisted Reproduction and Genetics, vol. 24, no. 7, pp. 303–315, 2007. View at: Publisher Site | Google Scholar
  51. D. M. Sherer and O. Abulafia, “Angiogenesis during implantation, and placental and early embryonic development,” Placenta, vol. 22, no. 1, pp. 1–13, 2001. View at: Publisher Site | Google Scholar
  52. N. Klauber, R. M. Rohan, E. Flynn, and R. J. D'Amato, “Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470,” Nature Medicine, vol. 3, no. 4, pp. 443–446, 1997. View at: Publisher Site | Google Scholar
  53. M. L. Rabbani and P. A. Rogers, “Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats,” Reproduction, vol. 122, no. 1, pp. 85–90, 2001. View at: Publisher Site | Google Scholar
  54. K. Murakami, Y. H. Lee, E. S. Lucas et al., “Decidualization induces a secretome switch in perivascular niche cells of the human endometrium,” Endocrinology, vol. 155, no. 11, pp. 4542–4553, 2014. View at: Publisher Site | Google Scholar
  55. Y. Ning, M. A. Williams, S. Vadachkoria, M. Muy-Rivera, I. O. Frederick, and D. A. Luthy, “Maternal plasma concentrations of insulinlike growth factor-1 and insulinlike growth factor-binding protein-1 in early pregnancy and subsequent risk of preeclampsia,” Clinical Biochemistry, vol. 37, no. 11, pp. 968–973, 2004. View at: Publisher Site | Google Scholar
  56. L. J. Vatten, T. I. L. Nilsen, A. Juul, S. Jeansson, P. A. Jenum, and A. Eskild, “Changes in circulating level of IGF-I and IGF-binding protein-1 from the first to second trimester as predictors of preeclampsia,” European Journal of Endocrinology, vol. 158, no. 1, pp. 101–105, 2008. View at: Publisher Site | Google Scholar
  57. S. Venkatesha, M. Toporsian, C. Lam et al., “Soluble endoglin contributes to the pathogenesis of preeclampsia,” Nature Medicine, vol. 12, no. 6, pp. 642–649, 2006. View at: Publisher Site | Google Scholar
  58. M. J. Cudmore, S. Ahmad, S. Sissaoui et al., “Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1,” European Heart Journal, vol. 33, no. 9, pp. 1150–1158, 2012. View at: Publisher Site | Google Scholar
  59. R. J. Levine, C. Lam, C. Qian et al., “Soluble endoglin and other circulating antiangiogenic factors in preeclampsia,” The New England Journal of Medicine, vol. 355, no. 10, pp. 992–1005, 2006. View at: Publisher Site | Google Scholar
  60. T.’u. J. Kaitu’u-Lino, R. Hastie, N. J. Hannan et al., “Loss of Akt increases soluble endoglin release from endothelial cells but not placenta,” Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, vol. 6, no. 2, pp. 95–102, 2016. View at: Publisher Site | Google Scholar
  61. S. B. Chadchan, V. Kumar, V. K. Maurya, U. K. Soni, and R. K. Jha, “Endoglin (CD105) coordinates the process of endometrial receptivity for embryo implantation,” Molecular and Cellular Endocrinology, vol. 425, pp. 69–83, 2016. View at: Publisher Site | Google Scholar
  62. A. C. Harmon, D. C. Cornelius, L. M. Amaral et al., “The role of inflammation in the pathology of preeclampsia,” Clinical Science, vol. 130, no. 6, pp. 409–419, 2016. View at: Publisher Site | Google Scholar
  63. Y. Sasaki, D. Darmochwal-Kolarz, D. Suzuki et al., “Proportion of peripheral blood and decidual CD4+ CD25bright regulatory T cells in pre-eclampsia,” Clinical and Experimental Immunology, vol. 149, no. 1, pp. 139–145, 2007. View at: Publisher Site | Google Scholar
  64. S. J. Huang, C. P. Chen, F. Schatz, M. Rahman, V. M. Abrahams, and C. J. Lockwood, “Pre-eclampsia is associated with dendritic cell recruitment into the uterine decidua,” The Journal of Pathology, vol. 214, no. 3, pp. 328–336, 2008. View at: Publisher Site | Google Scholar
  65. C. J. Lockwood, C.-F. Yen, M. Basar et al., “Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells,” The American Journal of Pathology, vol. 172, no. 6, pp. 1571–1579, 2008. View at: Publisher Site | Google Scholar
  66. G. Gopinathan, C. Milagre, O. M. T. Pearce et al., “Interleukin-6 stimulates defective angiogenesis,” Cancer Research, vol. 75, no. 15, pp. 3098–3107, 2015. View at: Publisher Site | Google Scholar
  67. U. R. Markert, D. M. Morales-Prieto, and J. S. Fitzgerald, “Understanding the link between the IL-6 cytokine family and pregnancy: implications for future therapeutics,” Expert Review of Clinical Immunology, vol. 7, no. 5, pp. 603–609, 2011. View at: Publisher Site | Google Scholar

Copyright © 2019 Manuel Varas-Godoy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

773 Views | 235 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.